Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Today, Biocartis, an innovative molecular diagnostics company, and Discovery Life Sciences (“Discovery”), a global leader in biomarker specialty laboratory services and biospecimen solutions, are pleased to announce a strategic collaboration to deliver seamless, end-to-end precision oncology solutions to pharmaceutical and biotech customers worldwide.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Genedrive (LSE:GDR) has entered into a collaboration agreement with Thermo Fisher Scientific to develop the Genedrive CYP2C19 HT Kit, a high-throughput pharmacogenetic in vitro diagnostic test designed for use on Thermo Fisher’s QuantStudio 5 Dx PCR platform. The new assay is aimed at centralised laboratory testing and complements the company’s existing rapid CYP2C19 ID Kit for near-patient use. Genedrive is targeting UKCA certification by the end of 2026, with the initial commercial focus on NHS genomic laboratories across the UK.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.

French biopharma Sanofi has inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD), which will be distributed to select healthcare systems and low-income community care clinics.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Kingdom of Saudi Arabia ("KSA"), visited Co-Diagnostics' Salt Lake City headquarters ahead of a planned technology transfer to CoMira. The visit included a tour of the Company's facilities and unveiling a future automated manufacturing line at a technology and innovation event also attended by state officials, trade representatives, and community leaders.

Nivi, Inc., a digital health innovator specializing in personalized healthcare guidance and consumer insights, and MSD (known as Merck Sharp & Dohme LLC in the United States and Canada, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA) today announced a global initiative to enhance consumer awareness of HPV diseases and HPV-related cervical cancer prevention across emerging markets, beginning with India, Indonesia, and Thailand.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.